Interleukin-27 (IL-27), a member of the IL-12 cytokine family, was long viewed primarily as a regulator of CD4+ T cell immunity. Subsequent studies revealed that IL-27 also directly modulates CD8+ T cells, displaying both stimulatory and inhibitory potential. Recent work extends this earlier literature, showing that IL-27 in infection and cancer can promote effector differentiation, sustain survival, and reverse dysfunction, often without the systemic toxicity associated with related cytokines. This review outlines the molecular features, signaling mechanisms, and cellular sources of IL-27, integrating emerging evidence from viral, tumor, and autoimmune settings. We propose that IL-27 operates not as an inherently pro- or anti-inflammatory cytokine but as a context-dependent tuner of CD8+ T cell cytotoxic immunity, offering new opportunities for therapeutic exploitation.

Give us your feedback on our SPAAMtisch initiative which runs almost every month alternating seminars and round tables

Dr Mariana Borsa, Postdoctoral Researcher in autophagy and ageing, will leave the Kennedy Institute to start an exciting new chapter in Switzerland as a Principal Investigator.